跳至主要内容
临床试验/NCT00797589
NCT00797589已完成4 期

Effect of Prime Solution on Fluid Balance After Open Heart Surgery

University of Helsinki1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
35
试验地点
1
主要终点
fluid balance

研究概览

简要总结

The use of Tetraspan® as prime solution can reduce fluid extravasation after perfusion versus Ringer acetate. Plasma-adapted HES-solutions produce also less acidosis.

详细描述

Fifty patients scheduled for elective primary and single cardiac surgery include in this prospective study. Patients with preoperative coagulation disorders, or renal or hepatic failure, are excluded.

Before admission to the operation theatre, the patients allocate in random order to receive one of the following solutions during the extracorporeal circulation:

  1. Ringer-acetate solution
  2. 6% HES solution (Tetraspan®) During the 1 postoperative day we register hemodynamic changes, fluid balance, fluid extravasation, plasma ion concentration, modified thromboelastography, and kidney function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Elective combined cardiac surgery

排除标准

  • Liver failure
  • Kidney failure

研究组 & 干预措施

HES solution (Tetraspan®)

Experimental

Balanced colloid solution

干预措施: HES (Drug)

Ringer lactate

Experimental

Crystalloid solution

干预措施: Ringer lactate (Drug)

结局指标

主要结局

fluid balance

时间窗: 1 postoperative day

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alexey Schramko

MD, PhD

University of Helsinki

研究点 (1)

Loading locations...

相似试验